

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)

(Amendment No. 1)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Name of Issuer)

COMMON STOCK, \$0.10 PAR VALUE

(Title of Class of Securities)

50540R 10 2

(CUSIP Number)

Peter R. Douglas
Davis Polk & Wardwell
450 Lexington Avenue
New York, NY 10017
Tel. No.: (212) 450-4000

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

June 6, 2000

(Date of Event which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1 (b) (3) or (4), check the following box ☐

Note. This document is being electronically filed with the Commission using the EDGAR system. See Rule 13d-1 (a) for other parties to whom copies are to be sent.

*The remainder of this cover page should be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Roche Holdings, Inc. 51-0304944		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) [] (b) []
3	SEC USE ONLY	
4	SOURCE OF FUNDS WC	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e).	[]
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
	NUMBER OF SHARES	7 SOLE VOTING POWER 6,132,926 shares of Common Stock
	BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8 SHARED VOTING POWER N/A 9 SOLE DISPOSITIVE POWER 6,132,926 shares of Common Stock 10 SHARED DISPOSITIVE POWER N/A
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,132,926 shares of Common Stock	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	[]
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 45.97% of Common Stock	
14	TYPE OF REPORTING PERSON CO, HC	

The following information amends and supplements the Schedule 13D dated April 28, 1995 (the "Schedule 13D").

Item 1. Security and Issuer.

Item 1 of the Schedule 13D is hereby amended and restated in its entirety as follows:

This statement relates to the Common Stock, par value \$0.10 per share (the "Common Stock") of Laboratory Corporation of America Holdings, a Delaware corporation (the "Company"). The principal executive offices of the Company are located at 358 South Main Street, Burlington, North Carolina 27215.

Item 4. Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended by adding the following:

Holdings plans to sell up to approximately 2.5 million shares of Common Stock to a limited number of investors. Holdings currently owns 6,132,926 shares or 45.97% of the Company's Common Stock and 8 1/2% Series B Pay-in-Kind Preferred Stock ("Series B Preferred Stock") convertible into 11,719,713 shares of Common Stock. At June 30, 2000, assuming Holdings sells the full amount of

the 2.5 million shares of Common Stock and all of the Company's 8 1/2% Series A Convertible Exchangeable Preferred Stock and Series B Preferred Stock (including the Series B Preferred Stock held by Holdings) is converted, Holdings' ownership of Common Stock would be approximately 45%.

The Company has filed a registration statement with the Securities and Exchange Commission relating to the proposed offer and sale by Holdings of the Company's Common Stock, but the registration statement has not yet become effective. Such securities may not be sold nor may offers to buy such securities be accepted prior to the time such registration statement becomes effective.

3

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and accurate.

Dated: June 7 , 2000

ROCHE HOLDINGS, INC.

By: /S/ Marcel Kohler

Name: Marcel Kohler

Title: Secretary